Geulah Livshits
Stock Analyst at Chardan Capital
(1.21)
# 3,410
Out of 4,829 analysts
194
Total ratings
26.06%
Success rate
-10.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $54 → $45 | $6.99 | +543.78% | 16 | May 9, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $28 → $25 | $3.08 | +711.69% | 9 | May 9, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $30 → $25 | $1.75 | +1,328.57% | 12 | May 9, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $68 | $8.12 | +737.44% | 14 | May 9, 2025 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $9 | $0.41 | +2,074.44% | 11 | May 9, 2025 | |
| KRYS Krystal Biotech | Maintains: Buy | $219 | $132.18 | +65.68% | 10 | May 7, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $84 → $82 | $35.62 | +130.21% | 13 | May 7, 2025 | |
| IMRX Immuneering | Maintains: Buy | $13 | $1.14 | +1,040.35% | 11 | May 6, 2025 | |
| SNTI Senti Biosciences | Maintains: Buy | $12 | $3.26 | +268.10% | 8 | May 2, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $50 | $22.77 | +119.59% | 1 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $22 | $2.69 | +717.84% | 8 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $0.54 | +1,203.54% | 5 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $1.30 | +1,130.77% | 4 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 | $2.76 | +479.71% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $0.33 | +1,722.60% | 4 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 | $2.13 | +228.64% | 12 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.03 | - | 3 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.45 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 | $1.51 | +893.38% | 5 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $5.42 | +656.46% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $25 | $4.26 | +487.54% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.19 | +908.40% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $24.25 | +757.73% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $1.20 | +1,233.33% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $2.5 | $7.33 | -65.89% | 5 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $7.52 | +1,096.81% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $3.17 | +26.18% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $30 | $2.81 | +967.62% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $7.46 | +141.29% | 1 | Oct 27, 2020 |
Rocket Pharmaceuticals
May 9, 2025
Maintains: Buy
Price Target: $54 → $45
Current: $6.99
Upside: +543.78%
4D Molecular Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $3.08
Upside: +711.69%
Iovance Biotherapeutics
May 9, 2025
Maintains: Buy
Price Target: $30 → $25
Current: $1.75
Upside: +1,328.57%
Intellia Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $68
Current: $8.12
Upside: +737.44%
Tenaya Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $9
Current: $0.41
Upside: +2,074.44%
Krystal Biotech
May 7, 2025
Maintains: Buy
Price Target: $219
Current: $132.18
Upside: +65.68%
CRISPR Therapeutics AG
May 7, 2025
Maintains: Buy
Price Target: $84 → $82
Current: $35.62
Upside: +130.21%
Immuneering
May 6, 2025
Maintains: Buy
Price Target: $13
Current: $1.14
Upside: +1,040.35%
Senti Biosciences
May 2, 2025
Maintains: Buy
Price Target: $12
Current: $3.26
Upside: +268.10%
Palvella Therapeutics
Apr 9, 2025
Initiates: Buy
Price Target: $50
Current: $22.77
Upside: +119.59%
Apr 8, 2025
Maintains: Buy
Price Target: $25 → $22
Current: $2.69
Upside: +717.84%
Mar 24, 2025
Maintains: Buy
Price Target: $11 → $7
Current: $0.54
Upside: +1,203.54%
Mar 20, 2025
Maintains: Buy
Price Target: $15 → $16
Current: $1.30
Upside: +1,130.77%
Mar 7, 2025
Maintains: Buy
Price Target: $16
Current: $2.76
Upside: +479.71%
Mar 4, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $0.33
Upside: +1,722.60%
Feb 26, 2025
Maintains: Buy
Price Target: $7
Current: $2.13
Upside: +228.64%
Jan 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.03
Upside: -
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.45
Upside: -
Nov 20, 2024
Maintains: Buy
Price Target: $15
Current: $1.51
Upside: +893.38%
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $5.42
Upside: +656.46%
Mar 23, 2023
Maintains: Buy
Price Target: $28 → $25
Current: $4.26
Upside: +487.54%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $1.19
Upside: +908.40%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $24.25
Upside: +757.73%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $1.20
Upside: +1,233.33%
Aug 22, 2022
Maintains: Buy
Price Target: $4 → $2.5
Current: $7.33
Upside: -65.89%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $7.52
Upside: +1,096.81%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $3.17
Upside: +26.18%
Jul 23, 2021
Maintains: Neutral
Price Target: $50 → $30
Current: $2.81
Upside: +967.62%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $7.46
Upside: +141.29%